Anavex, a clinical-stage biopharmaceutical company, is making strides in the treatment of neurodegenerative diseases, particularly Alzheimer’s. With a focus on innovative therapies, Anavex has recently shared promising results from their Phase 2b/3 clinical trial of blarcamesine (ANAVEX®2-73), a potential breakthrough in Alzheimer’s treatment. The trial, involving 508 participants across five […]